FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

TATEMENT	OF CHA	NGES IN	BENEFICIAL	OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-0									
	Estimated average burden									
- 1	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	Address of	Reporting Person*							ker or Trading , <u>Inc.</u> [ VI			(Ch	elationship of the contract of	able)	Person(s) to Iss	
(Last) 260 SHE	`	rst) ZENUE, SUITE	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/23/2024					]	below)	(give title	Other (below)	specify	
(Street) PALO All (City)			94306 (Zip)		-				of Original File	`		Line	Y Form f	led by One R	ling (Check Ap eporting Perso han One Repo	n
Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										d to						
			le I - Nor						quired, Di	<del>.</del>	<u> </u>					
Date			2. Trans Date (Month	/Day/Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Of (D Code (Instr. 5)			es Acquired (A) or Of (D) (Instr. 3, 4 and		s Fally (I	Ownership orm: Direct 0) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Date,	4. Transaction Code (Instr. ) 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$7.38	05/23/2024 <sup>(1)</sup>			A		53,254		(2)	03/06/2034	Common Stock	53,254	\$0.00	200,000	D	

## **Explanation of Responses:**

- 1. The option grant was approved on March 7, 2024, subject to stockholder approval of an amendment to the Vincerx Pharma, Inc. 2020 Stock Incentive Plan. The stockholders approved the amendment on May 23, 2024.
- 2. One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter

By: /s/ Dr. Ahmed M. Hamdy 05/29/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.